

Note: This document has been translated from the Japanese original version for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original version, the original version shall prevail. PeptiDream Inc. assumes no responsibility for this translation or for direct, indirect or any other forms of damage arising from the translation.

(Stock Exchange Code: 4587)

March 5, 2024

(Commencement of electronic provision: March 4, 2024)

**To Shareholders with Voting Rights:**

Patrick Reid  
Representative Director, President & CEO  
PeptiDream Inc.  
3-25-23 Tonomachi, Kawasaki-ku,  
Kawasaki City, Kanagawa

**NOTICE OF  
THE 18th ORDINARY GENERAL MEETING OF SHAREHOLDERS**

Dear Shareholders:

We would like to express our appreciation for your continued support and patronage.

You are cordially notified of the 18th Ordinary General Meeting of Shareholders of PeptiDream Inc. (the “Company”). The meeting will be held for the purposes as described below.

In convening this meeting, the Company has taken electronic provision measures, and posted the matters subject to electronic provision measures on the following Company’s website on the Internet.

PeptiDream’s website

<https://www.peptidream.com/en/ir/stock-information/shareholders-meeting-related-presentations/>

In addition to the above, the information is also posted on the following website on the Internet

Tokyo Stock Exchange’s website

<https://www2.jpx.co.jp/tseHpFront/JJK020010Action.do?Show=Show>

Please access the Tokyo Stock Exchange’s website above. Enter or search for our company name or Stock Exchange Code, and select “Basic information” and “Documents for public inspection/PR information” in that order.

If you exercise your voting rights in writing or via the Internet, etc., please review the Reference Documents for the General Meeting of Shareholders posted on the matters subject to electronic provision measures, and exercise your voting rights by 6:00 p.m. on Tuesday, March 26, 2024, Japan time.

- 1. Date and Time:** Wednesday, March 27, 2024 at 10:00 a.m. Japan time
- 2. Place:** Prince Room, B1F Grand Prince Hotel Takanawa,  
3-13-1 Takanawa, Minato-ku, Tokyo
- 3. Agenda:**
- Matters to be reported:**
1. Business Report, Consolidated Financial Statements, and Results of Audit Reports of the Consolidated Financial Statements by the Accounting Auditor and the Audit and Supervisory Committee for the Company's 18th Fiscal Year (January 1, 2023–December 31, 2023)
  2. Non-consolidated Financial Statements for the Company's 18th Fiscal Year (January 1, 2023–December 31, 2023)
- Proposals to be resolved:**
- Proposal:** Election of 3 Directors (Excluding Directors Appointed as Audit and Supervisory Committee Members)

# Reference Documents for the General Meeting of Shareholders

## Proposals and References

### Proposal: Election of 3 Directors (Excluding Directors Appointed as Audit and Supervisory Committee Members)

The terms of office of all 3 Directors (excluding Directors appointed as Audit and Supervisory Committee Members; hereinafter the same shall apply to this Proposal) will expire at the end of this Ordinary General Meeting of Shareholders.

Accordingly, the Company proposes the election of 3 Directors.

The candidates are as follows:

No.	Name (Date of birth)	Past experience, positions, responsibilities and significant concurrent positions	Number of shares of the Company held (Of which, number of those to be delivered by the share benefit trust)
1	Patrick Reid (January 14, 1975)	<p>August 2003 NRSA Post-doctoral Fellow of Dartmouth Medical School</p> <p>April 2004 Project Associate Professor of Research Center for Advanced Science and Technology, the University of Tokyo</p> <p>January 2005 Visiting Associate Professor of Center for Collaborative Research, the University of Tokyo</p> <p>April 2006 Project Associate Professor of Research Center for Advanced Science and Technology, the University of Tokyo</p> <p>January 2007 Joined the Company</p> <p>August 2008 Director of the Company</p> <p>May 2012 Director and General Manager of Scientific Department of the Company</p> <p>September 2012 Senior Vice President and General Manager of Scientific Department of the Company</p> <p>July 2014 Senior Vice President, Head of Research &amp; Development of the Company</p> <p>September 2017 Representative Director, President and CEO of the Company</p> <p>January 2022 Representative Director, President and CEO of the Company (no change to English title) (to present)</p>	4,246,584 (56,584)
2	Keiichi Masuya (April 2, 1969)	<p>April 1998 Joined Mitsubishi Chemical Corporation</p> <p>September 2001 Joined Novartis Pharma K.K.</p> <p>April 2006 Joined Novartis International AG</p> <p>November 2008 Head of PPI Drug Discovery and Novartis Leading Scientist of Novartis International AG</p> <p>July 2014 General Manager of Scientific Department of the Company</p> <p>September 2015 Director and Vice President, Head of Chemistry of the Company</p> <p>March 2018 Director and Executive Vice President of the Company</p> <p>October 2018 Director and Executive Vice President of the Company (no change to English title)</p> <p>April 2020 Director of PeptiGrowth Inc. (to present)</p> <p>November 2020 Representative Director and President of PeptiAID Inc. (to present)</p> <p>January 2022 Director, COO of the Company (to present)</p> <p>March 2022 Managing Director of PDRadiopharma Inc. (to present)</p> <p>(Significant concurrent positions) Representative Director and President of PeptiAID Inc.</p>	53,202 (53,202)

No.	Name (Date of birth)	Past experience, positions, responsibilities and significant concurrent positions	Number of shares of the Company held (Of which, number of those to be delivered by the share benefit trust)
3	Kiyofumi Kaneshiro (August 16, 1977)	<p>April 2003      Research Fellow of the Japan Society for the Promotion of Science (DC)</p> <p>April 2005      Researcher of Center for Collaborative Research, the University of Tokyo</p> <p>April 2006      Joined The Boston Consulting Group (BCG)</p> <p>January 2016    Partner &amp; Managing Director of BCG</p> <p>January 2018    Executive Vice President of the Company</p> <p>October 2018    Director and Executive Vice President of the Company</p> <p>November 2020   Director of PeptiAID Inc. (to present)</p> <p>January 2022    Director, CFO of the Company (to present)</p> <p>March 2022     Managing Director of PDRadiopharma Inc. (to present)</p>	43,202 (43,202)

(Notes)

1. The Company has transactions with PeptiAID Inc., at which Dr. Keiichi Masuya serves as the Representative Director. None of the other candidates has special interest in the Company.
2. Dr. Patrick Reid joined the Company shortly after its foundation and has been leading research and development operations. He is assuming the responsibility of management as a Director of the Company and has deep insight and ability. In light of this, the Company believes that Dr. Reid is capable of successfully fulfilling his duties as Director, with respect to the decision-making process of the Board of Directors.
3. Dr. Keiichi Masuya has a wealth of operational experience in the Scientific Department of the Company and deep insight in the field. In light of this, the Company believes that Dr. Masuya is capable of successfully fulfilling his duties as Director, with respect to the decision-making process of the Board of Directors.
4. Dr. Kiyofumi Kaneshiro has extensive experience in all aspects of management and a high level of insight. In light of this, the Company believes that Dr. Kaneshiro is capable of successfully fulfilling his duties as Director by utilizing his experience and insight, with respect to the decision-making process of the Board of Directors.
5. The Company has concluded a directors and officers liability insurance (D&O insurance) contract that insures all directors in order to allow the officers to fulfill their expected roles when performing their duty and to enable the Company to attract talented human resources. If this proposal is approved as originally proposed and the candidates assume office as Directors, each candidate shall be an insured person under this contract. Under this contract, any damage that may arise as a result of the insured officers assuming responsibilities related to the performance of their duties or receiving claims pertaining to the pursuit of such responsibilities shall be covered. However, there are certain exemptions where no damage shall be covered if such damage was caused as a result of acts committed while being aware of violation of laws and regulations. The Company bears all insurance premiums, including the portion for riders, and the insured persons shall not effectively bear any insurance premiums. The Company intends to update this contract on March 28, 2024 during the candidates' terms of office.